A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes

CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable.

The researchers created meditope-enabled CAR-T cells, or meCAR-T cells. These cells contain a special molecular docking site that can bind externally administered adapters after the CAR-T cells have already been infused. In simple terms, the CAR-T cells become a kind of “plug-and-play” platform that can be modified without having to manufacture an entirely new batch of cells.

This could allow doctors to add new functions to the same CAR-T cells over time. Depending on the adapter used, the cells could potentially be redirected toward another tumour antigen, helped to expand, tracked inside the body or given additional signals to improve their activity.

That concept could be particularly useful in solid tumors, where targeting a single antigen is often not enough. Prostate cancer is a good example. Targets such as PSMA, STEAP1 and PSCA can be highly expressed, but not necessarily on every cancer cell. A modular CAR-T system could theoretically start by attacking one target and later be redirected toward another if the tumour changes or loses the original antigen.

The current study is not specific to prostate cancer, and there are no prostate-specific data yet. The idea is therefore still speculative from our perspective. However, the platform directly addresses one of the main reasons CAR-T therapies struggle in heterogeneous solid tumours.

The technology is also moving toward the clinic. The researchers are preparing Phase 1 studies in solid tumours and acute myeloid leukaemia, which should provide the first indication of whether this adaptable CAR-T approach can work safely in patients.

Source.